Clinical Trial Results:
One-, Three-, Five- and Ten-Year Data on the Long-Term Immunogenicity of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Tdap) in Adolescents 11–14 Years of Age
Summary
|
|
EudraCT number |
2015-005844-32 |
Trial protocol |
Outside EU/EEA |
Global end of trial date |
20 Feb 2009
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
16 Apr 2016
|
First version publication date |
16 Apr 2016
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
Td9805-LT
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
- | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Sanofi Pasteur Limited
|
||
Sponsor organisation address |
1755 Steeles Ave. West, Toronto, Canada, M2R 3T4
|
||
Public contact |
Director, Clinical Development, Sanofi Pasteur Limited, 1 416-667-2273, Miggi.Tomovici@sanofipasteur.com
|
||
Scientific contact |
Director, Clinical Development, Sanofi Pasteur Limited, 1 416-667-2273, Miggi.Tomovici@sanofipasteur.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
Yes
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
20 Feb 2009
|
||
Is this the analysis of the primary completion data? |
No
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
20 Feb 2009
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
To describe the antibody levels for tetanus, diphtheria and pertussis at 1 year, 3 years, 5 years and 10 years after vaccination with Tdap Vaccine.
|
||
Protection of trial subjects |
Subjects were vaccinated in a previous study, Td9805. No vaccination was administered as part of this long-term immunogenicity follow-up study.
|
||
Background therapy |
In Td9805, subjects were randomized to receive either Tdap followed by Hepatitis B vaccine one month later (Group 1) or Tdap and Hepatitis B vaccines concomitantly (Group 2). For the long-term immunogenicity studies, subjects in both groups were recalled for serology at 1, 3, 5, and 10 years post-vaccination. | ||
Evidence for comparator |
Not applicable | ||
Actual start date of recruitment |
17 Nov 1999
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Canada: 267
|
||
Worldwide total number of subjects |
267
|
||
EEA total number of subjects |
0
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
193
|
||
Adolescents (12-17 years) |
74
|
||
Adults (18-64 years) |
0
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
||||||||||||||||
Recruitment
|
||||||||||||||||
Recruitment details |
The study subjects were enrolled from 17 November 1999 to 20 February 2009 at 1 clinic center in Canada. | |||||||||||||||
Pre-assignment
|
||||||||||||||||
Screening details |
A total of 267 subjects who met all inclusion and none of the exclusion criteria were enrolled in the long-term immunogenicity study. | |||||||||||||||
Period 1
|
||||||||||||||||
Period 1 title |
Overall trial (overall period)
|
|||||||||||||||
Is this the baseline period? |
Yes | |||||||||||||||
Allocation method |
Not applicable
|
|||||||||||||||
Blinding used |
Not blinded | |||||||||||||||
Blinding implementation details |
Not applicable
|
|||||||||||||||
Arms
|
||||||||||||||||
Are arms mutually exclusive |
Yes
|
|||||||||||||||
Arm title
|
Group 1; Tdap/Hepatitis | |||||||||||||||
Arm description |
Subjects received Tdap at month 0 and Hepatitis B at months 1, 2, and 7. | |||||||||||||||
Arm type |
Experimental | |||||||||||||||
Investigational medicinal product name |
Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Adacel®)
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
||||||||||||||||
Pharmaceutical forms |
Suspension for injection
|
|||||||||||||||
Routes of administration |
Intramuscular use
|
|||||||||||||||
Dosage and administration details |
0.5 mL, intramuscular, 1 injection at Month 0.
|
|||||||||||||||
Investigational medicinal product name |
Hepatitis B Vaccine (Recombivax HB®)
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
||||||||||||||||
Pharmaceutical forms |
Suspension for injection
|
|||||||||||||||
Routes of administration |
Intramuscular use
|
|||||||||||||||
Dosage and administration details |
0.5 mL, intramuscular, 1 injection each at Months 1, 7, and 7.
|
|||||||||||||||
Arm title
|
Group 2; Tdap and Hepatitis | |||||||||||||||
Arm description |
Subjects received Tdap and Hepatitis B at Month 0 and Hepatitis B at Months 1 and 6. | |||||||||||||||
Arm type |
Experimental | |||||||||||||||
Investigational medicinal product name |
Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Adacel®)
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
||||||||||||||||
Pharmaceutical forms |
Suspension for injection
|
|||||||||||||||
Routes of administration |
Intramuscular use
|
|||||||||||||||
Dosage and administration details |
0.5 mL, intramuscular, 1 injection at Month 0.
|
|||||||||||||||
Investigational medicinal product name |
Hepatitis B Vaccine (Recombivax HB®)
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
||||||||||||||||
Pharmaceutical forms |
Suspension for injection
|
|||||||||||||||
Routes of administration |
Intramuscular use
|
|||||||||||||||
Dosage and administration details |
0.5 mL, intramuscular, 1 injection at Month 0 concurrent with Tdap and 1 injection each at Months 1 and 6.
|
|||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Group 1; Tdap/Hepatitis
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects received Tdap at month 0 and Hepatitis B at months 1, 2, and 7. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Group 2; Tdap and Hepatitis
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects received Tdap and Hepatitis B at Month 0 and Hepatitis B at Months 1 and 6. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Group 1; Tdap/Hepatitis
|
||
Reporting group description |
Subjects received Tdap at month 0 and Hepatitis B at months 1, 2, and 7. | ||
Reporting group title |
Group 2; Tdap and Hepatitis
|
||
Reporting group description |
Subjects received Tdap and Hepatitis B at Month 0 and Hepatitis B at Months 1 and 6. |
|
|||||||||||||||||||||||||||||||||||||||||||||||||
End point title |
Percentage of Subjects with Seroprotection to Tetanus and Diphtheria Following Vaccination with Either Tetanus and Diphtheria Toxoids Adsorbed Combined with Component Pertussis (Tdap) Vaccine or Tdap and Hepatitis B Vaccines Given Concurrently [1] | ||||||||||||||||||||||||||||||||||||||||||||||||
End point description |
Anti-Diphtheria antibody responses were measured using a micrometabolic inhibition test. Anti-Tetanus antibody responses were measured using an enzyme-linked immunosorbent assay (ELISA). Seroprotection was defined as post-vaccination antibody titers ≥ 0.01 IU/mL for Diphtheria and ≥ 0.01 EU/mL for Tetanus.
|
||||||||||||||||||||||||||||||||||||||||||||||||
End point type |
Primary
|
||||||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
Day 0 (pre-vaccination) and 1 month and 1, 3, 5, and 10 years post-vaccination
|
||||||||||||||||||||||||||||||||||||||||||||||||
Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Descriptive analyses were performed, based on the vaccine groups from the primary series for the long term follow-up period. |
|||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||
End point title |
Percentage of Subjects with Seroprotection to Tetanus and Diphtheria Following Vaccination with Either Tetanus and Diphtheria Toxoids Adsorbed Combined with Component Pertussis (Tdap) Vaccine or Tdap and Hepatitis B Vaccines Given Concurrently | ||||||||||||||||||||||||||||||||||||||||||||||||
End point description |
Anti-Diphtheria antibody responses were measured using a micrometabolic inhibition test. Anti-Tetanus antibody responses were measured using an enzyme-linked immunosorbent assay (ELISA). Seroprotection was defined as post-vaccination antibody titers ≥ 0.1 IU/mL for Diphtheria and ≥ 0.1 EU/mL for Tetanus.
|
||||||||||||||||||||||||||||||||||||||||||||||||
End point type |
Other pre-specified
|
||||||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
Day 0 (pre-vaccination) and 1 month and 1, 3, 5, and 10 years post-vaccination
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||
End point title |
Summary of Geometric Mean Titers of Antibodies for Diphtheria and Tetanus Following Vaccination with Either Tetanus and Diphtheria Toxoids Adsorbed Combined with Component Pertussis (Tdap) Vaccine or Tdap and Hepatitis B Vaccines Given Concurrently | ||||||||||||||||||||||||||||||||||||||||||||||||
End point description |
Anti-Diphtheria antibody responses were measured using a micrometabolic inhibition test. Anti-Tetanus antibody responses were measured using an enzyme-linked immunosorbent assay (ELISA).
|
||||||||||||||||||||||||||||||||||||||||||||||||
End point type |
Other pre-specified
|
||||||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
Day 0 (pre-vaccination) and 1 month and 1, 3, 5, and 10 years post-vaccination
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point title |
Summary of Geometric Mean Titers of Antibodies for Pertussis Following Vaccination with Either Tetanus and Diphtheria Toxoids Adsorbed Combined with Component Pertussis (Tdap) Vaccine or Tdap and Hepatitis B Vaccines Given Concurrently | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point description |
Anti-Pertussis (Pertussis toxoid, Filamentous hemagglutinin, Fimbriae types 2 and 3, and Pertactin) antibody responses were measured using an indirect enzyme-linked immunosorbent assay (ELISA).
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point type |
Other pre-specified
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
Day 0 (pre-vaccination) and 1 month and 1, 3, 5, and 10 years post-vaccination
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point title |
Percentage of Subjects with Seropostivity to Pertussis Antigens Following Vaccination with Either Tetanus and Diphtheria Toxoids Adsorbed Combined with Component Pertussis (Tdap) Vaccine or Tdap and Hepatitis B Vaccines Given Concurrently | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point description |
Anti-Pertussis (Pertussis toxoid, Filamentous hemagglutinin, Fimbriae types 2 and 3, and Pertactin) antibody responses were measured using an indirect enzyme-linked immunosorbent assay (ELISA). Seropositivity rates, defined as the percentage of subjects with ≥ 1, 2, and 4 times the lower limit of quantitation (LLOQ) for the pertussis antigens, was 5 EU/mL for Pertussis toxoid, 3 EU/mL for Filamentous hemagglutinin and Pertactin, 17 EU/mL for Fimbriae types 2 and 3 for 1 month and 1, 3, and 5 years; 4 EU/mL for Pertussis toxoid, Fimbriae types 2 and 3, and Pertactin, and 3 EU/mL for Filamentous hemagglutinin for the 10 years.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point type |
Other pre-specified
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
Day 0 (pre-vaccination) and 1 month and 1, 3, 5, and 10 years post-vaccination
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||
Adverse events information [1]
|
|||
Timeframe for reporting adverse events |
This was a long-term immunogenicity follow-up study of patients that participated in a previous study, Td9805. No vaccines were administered in this study and adverse event data were also not collected.
|
||
Assessment type |
Non-systematic | ||
Dictionary used for adverse event reporting
|
|||
Dictionary name |
MedDRA | ||
Dictionary version |
10
|
||
Frequency threshold for reporting non-serious adverse events: 5% | |||
Notes [1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported. Justification: This was a long-term immunogenicity follow-up study of patients that participated in a previous study, Td9805. No vaccines were administered in this study and adverse event data were also not collected. |
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
23 May 2001 |
Details regarding the planned long-term follow-up serology studies were included which also involved the collection of additional blood samples at 1, 3, 5, and 10 years post-vaccination. |
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |